Is Eversense the Latest Game Changer in the Diabetes Market?

Senseonics’ newly approved Eversense implantable continuous glucose monitoring (CGM) system could be in patient’s hands as early as next month. Tim Goodnow, the Germantown, MD-based company’s president and CEO spoke with MD+DI just a few hours removed from the start of the American Diabetes Association’s 78th Scientific Sessions in Orlando, FL. about the approval and upcoming plans for the device. “We think we’ll have our first patients on the product in the third week of July, so it will take us just about a month,” Goodnow, told MD+DI. “We’ve got to print some of the instruction manuals that were approved by FDA now that we have the final wording.” The Eversense CGM system uses a small sensor that is implanted just under the skin by a qualified health care provider during an outpatient procedure. After it is implanted, the sensor regularly measures glucose levels in adults with diabetes for up to 90 days. Goodnow said there are plans in development for a sensor that can last up to 180 days and another that can last for up to a year. Although Eversense has just received FDA approval it has been on the market in Europe for about 21 months. “We think Eversense is going to be a very big deal to people,” Goodnow said. “Once a person is diagnosed with diabetes, it’s not curable, but you can manage it effectively and really minimize the long-term effect if you’re very aggressive in managing your glucose control. Diabetes patients already know this, th...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Implants Source Type: news